Literature DB >> 2469792

Control of pharmaceutical properties of soybean trypsin inhibitor by conjugation with dextran. I: Synthesis and characterization.

Y Takakura1, Y Kaneko, T Fujita, M Hashida, H Maeda, H Sezaki.   

Abstract

The Kunitz-type soybean trypsin inhibitor (STI), a model protein, was conjugated with dextran (Mw, approximately 9900; STI-D), and its physicochemical and biochemical properties were studied to develop a novel delivery system for a protein drug. Conjugation was carried out using periodate oxidation, and cyanogen bromide, carbodiimide, cyanuric chloride, epichlorhydrin, and N-succiniimidyl-3-(2-pyridyldithio)propionate (SPDP) reagent methods. Dextran was conjugated to STI at a molar ratio of 1.5 to 4.6, but the degree of modification, as well as yield and contamination extent of unreacted STI and dextran, varied with the method of synthesis. Gel filtration and electrophoresis confirmed the covalent attachment of dextran to STI but also demonstrated the broad molecular weight distribution of the conjugates. The STI-D conjugate retained satisfactory activity, although the attachment partially reduced its inhibitory activity against trypsin. The periodate oxidation method seemed to be the best for the preparation of STI-D since it gave the conjugate with a high modification ratio (4.6 molecules per STI), high yield (95%), and satisfactory activity recovery (63%). Chemical modification of STI was also carried out with activated polyethylene glycol (PEG) for comparison. The STI-PEG conjugate was obtained in a satisfactory yield (96%) and modification degree (5.8 molecules per STI), but the remaining activity was considerably lower (34%). Thus, conjugation of protein with dextran by the periodate oxidation method is suggested to be preferable for preparing a protein-carrier system without significant diminution of its biological activity.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2469792     DOI: 10.1002/jps.2600780209

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  7 in total

1.  Disposition characteristics of macromolecules in tumor-bearing mice.

Authors:  Y Takakura; T Fujita; M Hashida; H Sezaki
Journal:  Pharm Res       Date:  1990-04       Impact factor: 4.200

2.  Modification of Escherichia coli B glutathione synthetase with polyethylene glycol for clinical application to enzyme replacement therapy for glutathione deficiency.

Authors:  Y Inoue; K Sugiyama; H Ueminami; S Izawa; A Kimura
Journal:  Clin Diagn Lab Immunol       Date:  1996-11

Review 3.  Polymer conjugates. Pharmacokinetic considerations for design and development.

Authors:  R Duncan; F Spreafico
Journal:  Clin Pharmacokinet       Date:  1994-10       Impact factor: 6.447

Review 4.  Macromolecular therapeutics: advantages and prospects with special emphasis on solid tumour targeting.

Authors:  Khaled Greish; Jun Fang; Takao Inutsuka; Akinori Nagamitsu; Hiroshi Maeda
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

5.  Design for cell-specific targeting of proteins utilizing sugar-recognition mechanism: effect of molecular weight of proteins on targeting efficiency.

Authors:  M Nishikawa; H Hirabayashi; Y Takakura; M Hashida
Journal:  Pharm Res       Date:  1995-02       Impact factor: 4.200

6.  Characterization of Serine Protease Inhibitor from Solanum tuberosum Conjugated to Soluble Dextran and Particle Carriers.

Authors:  Erika Billinger; Shusheng Zuo; Gunnar Johansson
Journal:  ACS Omega       Date:  2019-10-25

7.  Dextranol: An inert xeroprotectant.

Authors:  Bryan J Jones; Advitiya Mahajan; Alptekin Aksan
Journal:  PLoS One       Date:  2019-09-06       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.